CRBP Corbus Pharmaceuticals | $8.52
+5.7% | 7/12/2025 | - | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 7/12/2025 |
CATX Perspective Therapeutics | $4.08
+4.6% | 7/12/2025 | O. Mccammon | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Perspective Therapeutics (NYSE:CATX) on 7/12/2025 |
DBVT DBV Technologies | $9.79
-3.6% | 6/26/2025 | S. Slutsky | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of DBV Technologies (NASDAQ:DBVT) on 6/26/2025 |
VERV Verve Therapeutics | $11.02
| 6/18/2025 | Cory Jubinville | Downgrade | Strong-Buy -> Hold | $12.00 | View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 6/18/2025 |
CBIO Crescent Biopharma | $13.14
+11.9% | 6/18/2025 | Charles Zhu | Upgrade | Strong-Buy | $22.00 | View details for Lifesci Capital rating of Crescent Biopharma (NASDAQ:CBIO) on 6/18/2025 |
TECX Tectonic Therapeutic | $22.57
+5.3% | 6/5/2025 | C. Jubinville | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 6/5/2025 |
TECX Tectonic Therapeutic | $22.57
+5.3% | 6/6/2025 | - | Initiated Coverage | Outperform | $87.00 | View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 6/6/2025 |
SRRK Scholar Rock | $41.15
+6.2% | 6/3/2025 | D. Kennedy | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Scholar Rock (NASDAQ:SRRK) on 6/3/2025 |
GLUE Monte Rosa Therapeutics | $5.61
+7.3% | 3/12/2025 | O. Mccammon | Initiated Coverage | Outperform | $19.00 | View details for Lifesci Capital rating of Monte Rosa Therapeutics (NASDAQ:GLUE) on 3/12/2025 |
TARA Protara Therapeutics | $3.15
+3.3% | 3/11/2025 | C. Zhu | Initiated Coverage | Outperform | $22.00 | View details for Lifesci Capital rating of Protara Therapeutics (NASDAQ:TARA) on 3/11/2025 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
IMNM Immunome | $9.67
+15.1% | 3/11/2025 | C. Zhu | Initiated Coverage | Outperform | $20.00 | View details for Lifesci Capital rating of Immunome (NASDAQ:IMNM) on 3/11/2025 |
MOLN Molecular Partners | $3.62
+1.4% | 3/11/2025 | C. Zhu | Initiated Coverage | Outperform | $12.00 | View details for Lifesci Capital rating of Molecular Partners (NASDAQ:MOLN) on 3/11/2025 |
ZYME Zymeworks | $13.52
+5.0% | 3/11/2025 | C. Zhu | Initiated Coverage | Outperform | $30.00 | View details for Lifesci Capital rating of Zymeworks (NYSE:ZYME) on 3/11/2025 |
CATX Perspective Therapeutics | $4.08
+4.6% | 3/6/2025 | D. Kennedy | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Perspective Therapeutics (NYSE:CATX) on 3/6/2025 |
TRML Tourmaline Bio | $18.54
-0.1% | 2/24/2025 | Jimmy Shan | Initiated Coverage | Outperform | $58.00 | View details for Lifesci Capital rating of Tourmaline Bio (NASDAQ:TRML) on 2/24/2025 |
SLNO Soleno Therapeutics | $85.52
+2.3% | 2/4/2025 | M. Belghiti | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Soleno Therapeutics (NASDAQ:SLNO) on 2/4/2025 |
AURA Aura Biosciences | $6.95
+5.9% | 1/31/2025 | O. Mccammon | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 1/31/2025 |
JANX Janux Therapeutics | $27.00
+4.8% | 12/27/2024 | O. Mccammon | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Janux Therapeutics (NASDAQ:JANX) on 12/27/2024 |
MREO Mereo BioPharma Group | $1.75
+2.3% | 12/23/2024 | C. Jubinville | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/23/2024 |
MREO Mereo BioPharma Group | $1.75
+2.3% | 12/24/2024 | - | Initiated Coverage | Outperform | $10.00 | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/24/2024 |
RPTX Repare Therapeutics | $1.53
+7.0% | 12/13/2024 | C. Zhu | Reiterated Rating | Outperform -> Market Perform | | View details for Lifesci Capital rating of Repare Therapeutics (NASDAQ:RPTX) on 12/13/2024 |
KURA Kura Oncology | $6.38
+4.1% | 10/22/2024 | C. Zhu | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Kura Oncology (NASDAQ:KURA) on 10/22/2024 |
OKUR OnKure Therapeutics | $2.49
-0.8% | 10/10/2024 | S. Slutsky | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of OnKure Therapeutics (NASDAQ:OKUR) on 10/10/2024 |
LQDA Liquidia Technologies | $14.19
-2.2% | 10/2/2024 | C. Jubinville | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Liquidia Technologies (NASDAQ:LQDA) on 10/2/2024 |
LQDA Liquidia Technologies | $14.19
-2.2% | 10/3/2024 | - | Initiated Coverage | Outperform | $30.00 | View details for Lifesci Capital rating of Liquidia Technologies (NASDAQ:LQDA) on 10/3/2024 |
ORKA Oruka Therapeutics | $14.80
+3.9% | 9/16/2024 | S. Slutsky | Initiated Coverage | Outperform | $41.00 | View details for Lifesci Capital rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/16/2024 |
AURA Aura Biosciences | $6.95
+5.9% | 9/9/2024 | A. Dhankher | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 9/9/2024 |
CELC Celcuity | $13.86
+0.6% | 8/26/2024 | O. Mccammon | Initiated Coverage | Outperform | $27.00 | View details for Lifesci Capital rating of Celcuity (NASDAQ:CELC) on 8/26/2024 |
CRBP Corbus Pharmaceuticals | $8.52
+5.7% | 8/21/2024 | M. Belghiti | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 8/21/2024 |
ALXO ALX Oncology | $0.47
+0.1% | 7/31/2024 | S. Slutsky | Downgrade | Strong-Buy -> Hold | | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 7/31/2024 |
RPTX Repare Therapeutics | $1.53
+7.0% | 7/29/2024 | C. Zhu | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Repare Therapeutics (NASDAQ:RPTX) on 7/29/2024 |
NUVL Nuvalent | $85.45
+3.0% | 7/29/2024 | C. Zhu | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Nuvalent (NASDAQ:NUVL) on 7/29/2024 |
MRUS Merus | $56.51
+2.8% | 7/29/2024 | C. Zhu | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Merus (NASDAQ:MRUS) on 7/29/2024 |
MRSN Mersana Therapeutics | $0.34
+4.0% | 7/29/2024 | C. Zhu | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Mersana Therapeutics (NASDAQ:MRSN) on 7/29/2024 |
IDYA IDEAYA Biosciences | $22.15
+3.4% | 7/29/2024 | C. Zhu | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of IDEAYA Biosciences (NASDAQ:IDYA) on 7/29/2024 |
DNTH Dianthus Therapeutics | $19.84
+4.2% | 6/11/2024 | R. Katkhuda | Upgrade | Strong-Buy | | View details for Lifesci Capital rating of Dianthus Therapeutics (NASDAQ:DNTH) on 6/11/2024 |
CALT Calliditas Therapeutics AB (publ) | $40.00
| 5/28/2024 | R. Katkhuda | Downgrade | Strong-Buy -> Hold | | View details for Lifesci Capital rating of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) on 5/28/2024 |
CATX Perspective Therapeutics | $4.08
+4.6% | 5/6/2024 | A. Dhankher | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Perspective Therapeutics (NYSE:CATX) on 5/6/2024 |
MLYS Mineralys Therapeutics | $14.32
-2.1% | 3/26/2024 | R. Katkhuda | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Mineralys Therapeutics (NASDAQ:MLYS) on 3/26/2024 |
GPCR Structure Therapeutics | $19.60
+1.9% | 2/27/2024 | M. Belghiti | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 2/27/2024 |
Is Elon's empire crumbling? (Ad) The Tesla Shock Nobody Sees Coming
While headlines scream "Tesla is doomed"...
Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs.
One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd. Click here to see the Tesla shock that could blindside everyone. |
VTYX Ventyx Biosciences | $3.13
+3.3% | 2/28/2024 | S. Slutsky | Upgrade | Market Perform -> Outperform | | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 2/28/2024 |
LRMR Larimar Therapeutics | $3.20
+1.3% | 2/20/2024 | C. Jubinville | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/20/2024 |
INBX Inhibrx Biosciences | $23.65
+3.0% | 1/23/2024 | S. Slutsky | Downgrade | Outperform -> Market Perform | | View details for Lifesci Capital rating of Inhibrx Biosciences (NASDAQ:INBX) on 1/23/2024 |
IVA Inventiva | $3.32
-0.3% | 1/5/2024 | R. Katkhuda | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Inventiva (NASDAQ:IVA) on 1/5/2024 |
TARS Tarsus Pharmaceuticals | $41.55
+2.4% | 12/26/2023 | C. Jubinville | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 12/26/2023 |
RCKT Rocket Pharmaceuticals | $2.86
+1.8% | 12/26/2023 | C. Jubinville | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/26/2023 |
SYRE Spyre Therapeutics | $16.20
+5.8% | 12/4/2023 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Spyre Therapeutics (NASDAQ:SYRE) on 12/4/2023 |
TCRX TScan Therapeutics | $1.81
+2.3% | 11/27/2023 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of TScan Therapeutics (NASDAQ:TCRX) on 11/27/2023 |
VTYX Ventyx Biosciences | $3.13
+3.3% | 11/7/2023 | S. Slutsky | Downgrade | Outperform -> Market Perform | | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/7/2023 |
VERV Verve Therapeutics | $11.02
| 8/8/2023 | C. Jubinville | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 8/8/2023 |
INBX Inhibrx Biosciences | $23.65
+3.0% | 8/8/2023 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Inhibrx Biosciences (NASDAQ:INBX) on 8/8/2023 |
TNYA Tenaya Therapeutics | $0.72
+4.4% | 8/8/2023 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 8/8/2023 |
PYXS Pyxis Oncology | $1.19
+2.6% | 4/26/2023 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 4/26/2023 |
OLMA Olema Pharmaceuticals | $4.56
-0.7% | 4/26/2023 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 4/26/2023 |
INBX Inhibrx Biosciences | $23.65
+3.0% | 4/26/2023 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Inhibrx Biosciences (NASDAQ:INBX) on 4/26/2023 |
AVDL Avadel Pharmaceuticals | $10.65
+2.6% | 4/26/2023 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 4/26/2023 |
ALXO ALX Oncology | $0.47
+0.1% | 4/26/2023 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 4/26/2023 |
IRON Disc Medicine | $57.34
+1.9% | 4/24/2023 | R. Katkhuda | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Disc Medicine (NASDAQ:IRON) on 4/24/2023 |
AKRO Akero Therapeutics | $53.60
+3.6% | 4/11/2023 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Akero Therapeutics (NASDAQ:AKRO) on 4/11/2023 |
IFRX InflaRx | $0.85
+4.4% | 4/5/2023 | - | Upgrade | Market Perform -> Outperform | | View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 4/5/2023 |
CRNX Crinetics Pharmaceuticals | $31.90
+0.2% | 3/27/2023 | C. Jubinville | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 3/27/2023 |
OBIO Orchestra BioMed | $3.15
+7.9% | 3/8/2023 | R. Rakhit | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 3/8/2023 |
ELVN Enliven Therapeutics | $21.46
-0.9% | 3/7/2023 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Enliven Therapeutics (NASDAQ:ELVN) on 3/7/2023 |
MLTX MoonLake Immunotherapeutics | $52.52
+5.7% | 12/21/2022 | R. Katkhuda | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 12/21/2022 |
PYXS Pyxis Oncology | $1.19
+2.6% | 12/1/2022 | A. Evertts | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 12/1/2022 |
ATXS Astria Therapeutics | $6.33
+0.3% | 11/28/2022 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Astria Therapeutics (NASDAQ:ATXS) on 11/28/2022 |
ALXO ALX Oncology | $0.47
+0.1% | 11/8/2022 | A. Evertts | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/8/2022 |
VYNE VYNE Therapeutics | $1.26
-2.3% | 8/12/2022 | P. Dolezal | Downgrade | Outperform -> Market Perform | | View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 8/12/2022 |
LRMR Larimar Therapeutics | $3.20
+1.3% | 8/12/2022 | P. Dolezal | Upgrade | Market Perform -> Outperform | | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/12/2022 |
TNYA Tenaya Therapeutics | $0.72
+4.4% | 6/16/2022 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 6/16/2022 |
VERA Vera Therapeutics | $23.56
+1.6% | 3/28/2022 | R. Katkhuda | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Vera Therapeutics (NASDAQ:VERA) on 3/28/2022 |
ELDN Eledon Pharmaceuticals | $3.78
-1.8% | 3/25/2022 | R. Katkhuda | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/25/2022 |
LRMR Larimar Therapeutics | $3.20
+1.3% | 2/16/2022 | Patrick Dolezal | Downgrade | Outperform -> Market Perform | $3.00 | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/16/2022 |
VERV Verve Therapeutics | $11.02
| 12/22/2021 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Verve Therapeutics (NASDAQ:VERV) on 12/22/2021 |
NNOX Nano-X Imaging | $4.99
+1.6% | 11/17/2021 | R. Rakhit | Downgrade | Outperform -> Market Perform | | View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 11/17/2021 |
VTYX Ventyx Biosciences | $3.13
+3.3% | 11/15/2021 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Ventyx Biosciences (NASDAQ:VTYX) on 11/15/2021 |
ALXO ALX Oncology | $0.47
+0.1% | 11/4/2021 | A. Evertts | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 11/4/2021 |
PYXS Pyxis Oncology | $1.19
+2.6% | 11/2/2021 | A. Evertts | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Pyxis Oncology (NASDAQ:PYXS) on 11/2/2021 |
RCKT Rocket Pharmaceuticals | $2.86
+1.8% | 10/24/2021 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/24/2021 |
DRIO DarioHealth | $0.72
+0.8% | 8/26/2021 | R. Rakhit | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of DarioHealth (NASDAQ:DRIO) on 8/26/2021 |
VRDN Viridian Therapeutics | $16.79
+3.3% | 8/24/2021 | R. Katkhuda | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Viridian Therapeutics (NASDAQ:VRDN) on 8/24/2021 |
LRMR Larimar Therapeutics | $3.20
+1.3% | 8/4/2021 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 8/4/2021 |
OLMA Olema Pharmaceuticals | $4.56
-0.7% | 6/21/2021 | A. Evertts | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Olema Pharmaceuticals (NASDAQ:OLMA) on 6/21/2021 |
NNOX Nano-X Imaging | $4.99
+1.6% | 6/3/2021 | R. Rakhit | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Nano-X Imaging (NASDAQ:NNOX) on 6/3/2021 |
ADVM Adverum Biotechnologies | $2.76
+4.9% | 4/29/2021 | P. Dolezal | Downgrade | Outperform -> Market Perform | | View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 4/29/2021 |
ELDN Eledon Pharmaceuticals | $3.78
-1.8% | 3/18/2021 | R. Katkhuda | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Eledon Pharmaceuticals (NASDAQ:ELDN) on 3/18/2021 |
COGT Cogent Biosciences | $11.86
+3.1% | 1/4/2021 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Cogent Biosciences (NASDAQ:COGT) on 1/4/2021 |
CLDX Celldex Therapeutics | $22.98
+0.6% | 11/17/2020 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Celldex Therapeutics (NASDAQ:CLDX) on 11/17/2020 |
TARS Tarsus Pharmaceuticals | $41.55
+2.4% | 11/10/2020 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 11/10/2020 |
AVDL Avadel Pharmaceuticals | $10.65
+2.6% | 11/9/2020 | D. Sherman | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 11/9/2020 |
"I'm risking my reputation on this" (Ad) Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented.
And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots…
What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book. Claim your FREE copy of Crypto Revolution now. |
CBIO Crescent Biopharma | $13.14
+11.9% | 11/5/2020 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Crescent Biopharma (NASDAQ:CBIO) on 11/5/2020 |
ADVM Adverum Biotechnologies | $2.76
+4.9% | 11/5/2020 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 11/5/2020 |
IFRX InflaRx | $0.85
+4.4% | 10/30/2020 | S. Slutsky | Reiterated Rating | Market Perform | | View details for Lifesci Capital rating of InflaRx (NASDAQ:IFRX) on 10/30/2020 |
RCKT Rocket Pharmaceuticals | $2.86
+1.8% | 10/16/2020 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/16/2020 |
INBX Inhibrx Biosciences | $23.65
+3.0% | 10/15/2020 | A. Evertts | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Inhibrx Biosciences (NASDAQ:INBX) on 10/15/2020 |
IMVT Immunovant | $17.81
+1.8% | 10/6/2020 | S. Slutsky | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Immunovant (NASDAQ:IMVT) on 10/6/2020 |
VYNE VYNE Therapeutics | $1.26
-2.3% | 10/2/2020 | P. Dolezal | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 10/2/2020 |
ALXO ALX Oncology | $0.47
+0.1% | 9/30/2020 | A. Evertts | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 9/30/2020 |
CRTX Cortexyme | $1.73
-2.8% | 9/24/2020 | D. Sherman | Reiterated Rating | Outperform | | View details for Lifesci Capital rating of Cortexyme (NASDAQ:CRTX) on 9/24/2020 |
